XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration and Strategic Alliances (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2025
Oct. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Deferred revenue     $ 4,303   $ 4,303   $ 0
License              
Net product and licensing revenue     13,154 $ 0 40,698 $ 0  
Novo Nordisk | License              
Proceeds from collaborators $ 45,000            
Variable consideration, regulatory milestones 485,000            
Variable consideration, sales milestones $ 475,000            
Net product and licensing revenue     13,200   40,700    
Deferred revenue     $ 4,300   $ 4,300    
Viatris Inc. | License              
Proceeds from collaborators   $ 25,000